Efficacy of exogenous atrial natriuretic peptide in patients with heart failure with preserved ejection fraction: deficiency of atrial natriuretic peptide and replacement therapy

Efficacy of exogenous atrial natriuretic peptide in patients with heart failure with preserved ejection fraction: deficiency of atrial natriuretic peptide and replacement therapy

Abstract Aims Exogenous atrial natriuretic peptide (ANP) may be a logical treatment for heart failure (HF) patients with ANP deficiency. Lower ANP concentrations may result from HF with preserved ejection fraction (HFpEF), which also results in lower brain natriuretic peptide levels in HFpEF relativ...

Full description

Bibliographic Details
Main Authors: Shingo Matsumoto, Gaku Nakazawa, Yohei Ohno, Mai Ishihara, Katsuaki Sakai, Norihito Nakamura, Tsutomu Murakami, Makoto Natsumeda, Takayuki Kabuki, Atsushi Shibata, Keisuke Kida, Masaaki Konishi, Shunsuke Ishii, Takanori Ikeda, Yuji Ikari
Format: Article
Language:English
Published: Wiley 2020-12-01
Series:ESC Heart Failure
Subjects:
Acute heart failure (AHF)
Carperitide
Brain natriuretic peptide (BNP)
Atrial fibrillation (AF)
Left atrial dysfunction
Online Access:https://doi.org/10.1002/ehf2.13042

Internet

https://doi.org/10.1002/ehf2.13042

Similar Items